Approach to patients with pancreatic cancer without detectable metastases

Journal of Clinical Oncology

Volumn 33, Issue 16, 2015, Pages 1770-1778

  Heestand, Gregory M ^a   Murphy, James D ^a   Lowy, Andrew M ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; HUMAN; METASTASIS; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS RESECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; CLINICAL PATHWAY; MORTALITY; PANCREATIC NEOPLASMS; PATHOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; RISK FACTOR; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CRITICAL PATHWAYS; HUMANS; NEOADJUVANT THERAPY; PANCREATECTOMY; PANCREATIC NEOPLASMS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RADIOTHERAPY, ADJUVANT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84937116007     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.7930     Document Type: Review

References (49)

1. Rahib L, Smith BD, Aizenberg R, et al: Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74:2913-2921, 2014
2. Neoptolemos JP, Stocken DD, Bassi C, et al: Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: A randomized controlled trial. JAMA 304:1073-1081, 2010
3. Lewis R, Drebin JA, Callery MP, et al: A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma. HPB (Oxford) 15:49-60, 2013
4. Tempero MA, Malafa MP, Behrman SW, et al: Pancreatic adenocarcinoma, version 2.2014: Featured updates to the NCCN guidelines. J Natl Compr Canc Netw 12:1083-1093, 2014
5. Tran Cao HS, Lopez N, Chang DC, et al: Improved perioperative outcomes with minimally invasive distal pancreatectomy: Results from a population-based analysis. JAMA Surg 149:237-243, 2014
6. Zhang J, Wu WM, You L, et al: Robotic versus open pancreatectomy: A systematic review and meta-analysis. Ann Surg Oncol 20:1774-1780, 2013
7. Kang CM, Lee SH, Lee WJ: Minimally invasive radical pancreatectomy for left-sided pancreatic cancer: Current status and future perspectives. World J Gastroenterol 20:2343-2351, 2014
8. Oettle H, Neuhaus P, Hochhaus A, et al: Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: The CONKO-001 randomized trial. JAMA 310:1473-1481, 2013
9. Schnelldorfer T, Ware AL, Sarr MG, et al: Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: Is cure possible? Ann Surg 247:456-462, 2008
10. Regine WF, Winter KA, Abrams RA, et al: Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: A randomized controlled trial. JAMA 299:1019-1026, 2008
11. Fukutomi A, Uesaka K, Boku N, et al: JASPAC-01: Randomized phase III of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer. J Clin Oncol 31, 2013 (suppl 15s; abstr 4008)
12. Oettle H, Post S, Neuhaus P, et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 297:267-277, 2007
13. Klinkenbijl JH, Jeekel J, Sahmoud T, et al: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230:776-782, 1999
14. Neoptolemos JP, Stocken DD, Friess H, et al: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200-1210, 2004
15. Kalser MH, Ellenberg SS: Pancreatic cancer: Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120:899-903, 1985
16. Burris HA 3rd, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
17. Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825, 2011
18. Von Hoff DD, Ervin T, Arena FP, et al: Increased survival in pancreatic cancer with nabpaclitaxel plus gemcitabine. N Engl J Med 369:1691-1703, 2013
19. Hardacre JM, Mulcahy M, Small W, et al: Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: A phase 2 study. J Gastrointest Surg 17:94-100, 2013
20. Lutz E, Yeo CJ, Lillemoe KD, et al: A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma: A phase II trial of safety, efficacy, and immune activation. Ann Surg 253:328-335, 2011
21. Lowy AM: Neoadjuvant therapy for pancreatic cancer. J Gastrointest Surg 12:1600-1608, 2008
22. Gillen S, Schuster T, Meyer Zum Büschenfelde C, et al: Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. PLoS Med 7:e1000267, 2010
23. Hosein PJ, Macintyre J, Kawamura C, et al: A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer 12:199, 2012
24. Varadachary GR, Tamm EP, Abbruzzese JL: Borderline resectable pancreatic cancer: Definitions, management, and role of preoperative therapy. Ann Surg Oncol 13:1035-1046, 2006
25. Katz MH, Marsh R, Herman JM, et al: Borderline resectable pancreatic cancer: Need for standardization and methods for optimal clinical trial design. Ann Surg Oncol 20:2787-2795, 2013
26. Abrams RA, Lowy AM, O'Reilly EM, et al: Combined modality treatment of resectable and borderline resectable pancreatic cancer: Expert consensus statement. Ann Surg Oncol 16:1751-1757, 2009
27. Katz MH, Pisters PW, Evans DB, et al: Borderline resectable pancreatic cancer: The importance of this emerging stage of disease. J Am Coll Surg 206:833-846, 2008
28. Chun YS, Milestone BN, Watson JC, et al: Defining venous involvement in borderline resectable pancreatic cancer. Ann Surg Oncol 17:2832-2838, 2010
29. Rose JB, Rocha FG, Alseidi A, et al: Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival. Ann Surg Oncol 21:1530-1537, 2014
30. Takahashi H, Ohigashi H, Gotoh K, et al: Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Ann Surg 258:1040-1050, 2013
31. Katz MH, Fleming JB, Bhosale P, et al: Response of borderline pancreatic cancer to neoadjuvant therapy is not reflected by radiographic criteria. Cancer 118:5749-5756, 2012
32. Chuong MD, Springett GM, Freilich JM, et al: Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys 86:516-522, 2013
33. Tseng CW, Balachandran A, Ahmad M, et al: Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford) 16:430-438, 2014
34. Tosolini C, Michalski CW, Kleeff J: Response evaluation following neoadjuvant treatment of pancreatic cancer patients. World J Gastrointest Surg 5:12-15, 2013
35. Loehrer PJ Sr, Feng Y, Cardenes H, et al: Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: An Eastern Cooperative Oncology Group trial. J Clin Oncol 29:4105-4112, 2011
36. Chauffert B, Mornex F, Bonnetain F, et al: Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer: Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 19:1592-1599, 2008
37. [No authors listed]: Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone-Gastrointestinal Tumor Study Group. J Natl Cancer Inst 80:751-755, 1988
38. Klaassen DJ, MacIntyre JM, Catton GE, et al: Treatment of locally unresectable cancer of the stomach and pancreas: A randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil-An Eastern Cooperative Oncology Group study. J Clin Oncol 3:373-378, 1985
39. Hazel JJ, Thirlwell MP, Huggins M, et al: Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: A prospective randomized trial. J Can Assoc Radiol 32:164-165, 1981
40. Mukherjee S, Hurt CN, Bridgewater J, et al: Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): A multicentre, randomised, phase 2 trial. Lancet Oncol 14:317-326, 2013
41. Huguet F, André T, Hammel P, et al: Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 25:326-331, 2007
42. Hammel P, Huguet F, Van Laethem JL, et al: Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study. J Clin Oncol 31, 2013 (suppl 15s; abstr LBA4003)
43. Abrams RA, Winter KA, Regine WF, et al: Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704: A phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 82:809-816, 2012
44. Brunner TB, Geiger M, Grabenbauer GG, et al: Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J Clin Oncol 26:2699-2706, 2008
45. Koong AC, Christofferson E, Le QT, et al: Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 63:320-323, 2005
46. Dholakia AS, Chang DT, Goodman KA, et al: A Phase 2 Multicenter Study to Evaluate Gemcitabine and Fractionated Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma. Int J Radiat Oncol Biol Phys 87:S28, 2013
47. Chang DT, Schellenberg D, Shen J, et al: Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer 115:665-672, 2009
48. Iacobuzio-Donahue CA, Fu B, Yachida S, et al: DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 27:1806-1813, 2009
49. Boone BA, Sabbaghian S, Zenati M, et al: Loss of SMAD4 staining in pre-operative cell blocks is associated with distant metastases following pancreaticoduodenectomy with venous resection for pancreatic cancer. J Surg Oncol 110:171-175, 2014